REGENXBIO sinks as FDA puts RGX-121 gene therapy on clinical hold (RGNX:NASDAQ)
· seekingalpha.com
FDA places REGENXBIO’s RGX-121 gene therapy on clinical hold after spine MRI nodules in Hunter syndrome trial; RGNX drops.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...